全文获取类型
收费全文 | 1646762篇 |
免费 | 138459篇 |
国内免费 | 5546篇 |
专业分类
耳鼻咽喉 | 21977篇 |
儿科学 | 53731篇 |
妇产科学 | 46816篇 |
基础医学 | 231956篇 |
口腔科学 | 48119篇 |
临床医学 | 147623篇 |
内科学 | 320480篇 |
皮肤病学 | 34615篇 |
神经病学 | 131905篇 |
特种医学 | 66165篇 |
外国民族医学 | 493篇 |
外科学 | 246809篇 |
综合类 | 50292篇 |
现状与发展 | 21篇 |
一般理论 | 548篇 |
预防医学 | 127526篇 |
眼科学 | 37622篇 |
药学 | 126890篇 |
58篇 | |
中国医学 | 6770篇 |
肿瘤学 | 90351篇 |
出版年
2018年 | 16070篇 |
2016年 | 14147篇 |
2015年 | 17045篇 |
2014年 | 23283篇 |
2013年 | 34226篇 |
2012年 | 46620篇 |
2011年 | 49067篇 |
2010年 | 29804篇 |
2009年 | 28270篇 |
2008年 | 46188篇 |
2007年 | 48363篇 |
2006年 | 48989篇 |
2005年 | 47209篇 |
2004年 | 45872篇 |
2003年 | 43803篇 |
2002年 | 42697篇 |
2001年 | 76722篇 |
2000年 | 79229篇 |
1999年 | 67011篇 |
1998年 | 18091篇 |
1997年 | 16678篇 |
1996年 | 16581篇 |
1995年 | 16269篇 |
1994年 | 15286篇 |
1993年 | 14328篇 |
1992年 | 55573篇 |
1991年 | 53919篇 |
1990年 | 52688篇 |
1989年 | 50946篇 |
1988年 | 47307篇 |
1987年 | 46663篇 |
1986年 | 44362篇 |
1985年 | 42899篇 |
1984年 | 32069篇 |
1983年 | 27598篇 |
1982年 | 16162篇 |
1981年 | 14454篇 |
1980年 | 13584篇 |
1979年 | 30473篇 |
1978年 | 21076篇 |
1977年 | 17771篇 |
1976年 | 16702篇 |
1975年 | 17584篇 |
1974年 | 21496篇 |
1973年 | 20689篇 |
1972年 | 18867篇 |
1971年 | 17777篇 |
1970年 | 16302篇 |
1969年 | 15277篇 |
1968年 | 13956篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
61.
62.
63.
目的对不同季铵化程度(DQ)的N-三甲基壳聚糖(TMC)促进阿昔洛韦(ACV)滴眼液眼部滞留性进行考察。方法将浓度为0.5%,DQ分别为20%、40%及60%的TMC(TMC20,TMC40,TMC60)加入ACV滴眼液中;以同浓度壳聚糖(CS)ACV滴眼液为阳性对照,以普通ACV滴眼液为阴性对照,选用家兔为实验动物,采用悬挂泡技术和束缚泡技术进行离体眼球表面接触角及解吸附动力学进行研究,同时在各种ACV滴眼液中分别加入0.05%的荧光素钠为示踪剂,在体研究各种ACV滴眼液在家兔眼部的滞留性。结果与普通ACV滴眼液相比,含CS及TMC的滴眼液在角膜表面的接触角明显降低,解吸时间及在体滞留时间明显延长(P<0.05);与同浓度的CS ACV阳性对照相比,TMC20促进滞留作用较弱,而TMC40作用差异无显著性(P>0.05),而TMC60的作用明显较强(P<0.05)结论 TMC可显著增加ACV的眼部滞留性,且与其DQ呈正相关。 相似文献
64.
65.
Past research suggests that as many as 50% of onward human immunodeficiency virus (HIV) transmissions occur during acute and recent HIV infection. It is clearly important to develop interventions which focus on this highly infectious stage of HIV infection to prevent further transmission in the risk networks of acutely and recently infected individuals. Project Protect tries to find recently and acutely infected individuals and prevents HIV transmission in their risk networks. Participants are recruited by community health outreach workers at community-based HIV testing sites and drug users' community venues, by coupon referrals and through referrals from AIDS clinics. When a network with acute/recent infection is identified, network members are interviewed about their risky behaviors, network information is collected, and blood is drawn for HIV testing. Participants are also educated and given prevention materials (condoms, syringes, educational materials); HIV-infected participants are referred to AIDS clinics and are assisted with access to care. Community alerts about elevated risk of HIV transmission are distributed within the risk networks of recently infected. Overall, 342 people were recruited to the project and screened for acute/recent HIV infection. Only six index cases of recent infection (2.3% of all people screened) were found through primary screening at voluntary counseling and testing (VCT) sites, but six cases of recent infection were found through contact tracing of these recently infected participants (7% of network members who came to the interview). Combining screening at VCT sites and contact tracing the number of recently infected people we located as compared to VCT screening alone. No adverse events were encountered. These first results provide evidence for the theory behind the intervention, i.e., in the risk networks of recently infected people there are other people with recent HIV infection and they can be successfully located without increasing stigma for project participants. 相似文献
66.
67.
I. R. Reid 《Journal of internal medicine》2015,277(6):690-706
There is an increasing number of effective therapies for fracture prevention in adults at risk of osteoporosis. However, shortcomings in the evidence underpinning our management of osteoporosis still exist. Evidence of antifracture efficacy in the groups of patients who most commonly use calcium and vitamin D supplements is lacking, the safety of calcium supplements is in doubt, and the safety and efficacy of high doses of vitamin D give cause for concern. Alendronate, risedronate, zoledronate and denosumab have been shown to prevent spine, nonspine and hip fractures; in addition, teriparatide and strontium ranelate prevent both spine and nonspine fractures, and raloxifene and ibandronate prevent spine fractures. However, most trials provide little information regarding long‐term efficacy or safety. A particular concern at present is the possibility that oral bisphosphonates might cause atypical femoral fractures. Observational data suggest that the incidence of this type of fracture increases steeply with duration of bisphosphonate use, resulting in concern that the benefit–risk balance may become negative in the long term, particularly in patients in whom the osteoporotic fracture risk is not high. Therefore, reappraisal of ongoing use of bisphosphonates after about 5 years is endorsed by expert consensus, and ‘drug holidays’ should be considered at this time. Further studies are needed to guide clinical practice in this area. 相似文献
68.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies
下载免费PDF全文
![点击此处可从《Journal of viral hepatitis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献